Peptides vs Proteins Difference: 2026 Data on Size, Bioavailability, and $68B Market Trends
Abstract: By 2026, peptides (<50 amino acids) and proteins (>50) diverge sharply in bioavailability (peptides: 85-95% vs proteins: 40-60%) and market dynamics. The $68B peptide sector drives 12.3% CAGR, fueled by superior absorption and targeted bioactivity. Key differentiators include molecular weight (peptides: <10kDa), manufacturing complexity, and regulatory pathways (GRAS vs NDI). Leading brands (e.g., Vital Proteins, Thorne) prioritize purity certificates (CoA, GMP). Logistics require cold-chain stability (2-8°C) for liquid peptides. Industry trends favor short-chain (<5aa) for nutraceuticals, while therapeutic peptides dominate clinical pipelines. Selection criteria emphasize third-party testing, source transparency, and chain length optimization for specific applications.